Posted by Staff
Minority Diabetes Reports
Wednesday, March 28th, 2012
Tde.sagepub.com: Stephania T. Miller, PhD1, Khensani Marolen, MSPH2, March 27, 2012.
The purpose of this study was to explore physical activity-related experiences, perceptions, and counseling expectations among urban, underactive, African American women with type 2 diabetes.
Methods
Participants were recruited via flyers and endocrinologist referral. A professional, African American female moderator led 2 focus groups among 11 participants. Focus groups were conducted in a video- and audio-equipped focus group room in the evening hours. Using a content-based, stepped analytic approach, 2 raters independently analyzed data and collaborated to compare results and finalize themes. Read More
Posted by Staff
Minority Diabetes Reports
Wednesday, March 28th, 2012
Tde.sagepub.com: Qiuping (Pearl) Zhou, PhD, Robin Remsburg, PhD, RN, Kristin Caufield, MSN, Elizabeth W. Itote, CNM.
The purposes of this study were to assess differences in lifestyle behaviors and other health-related factors between black and white adults with pre-diabetes and to identify predictors for lifestyle behaviors.
Methods
Using the 2007 and 2009 data from the Behavioral Risk Factor Surveillance System (BRFSS), an annual cross-sectional survey of randomly selected samples from each state, black (n = 1156) and white (n = 9539) adults with pre-diabetes were compared on lifestyle behaviors, general health practices, perceptions of health, chronic diseases, and access to care. Predictors for participating in regular physical activity and adequate intake of fruits and vegetables were identified for each racial and gender group using multiple regression procedures. Read More
Posted by Staff
Minority Diabetes Reports
Wednesday, March 28th, 2012
Care.diabetesjournals.org: March 23, 2012.
OBJECTIVE To examine diabetes screening, predictors of screening, and the burden of undiagnosed diabetes in the immigrant population and whether these estimates differ by ethnicity.
RESEARCH DESIGN AND METHODS A population-based retrospective cohort linking administrative health data to immigration files was used to follow the entire diabetes-free population aged 40 years and up in Ontario, Canada (N = 3,484,222) for 3 years (2004–2007) to determine whether individuals were screened for diabetes. Multivariate regression was used to determine predictors of having a diabetes test. Read More
Posted by Staff
Clinical Trials
Wednesday, March 28th, 2012
New England Journal of Medicine: Geltrude Mingrone, M.D., Simona Panunzi, Ph.D., Andrea De Gaetano, M.D., Ph.D., Caterina Guidone, M.D., Amerigo Iaconelli, M.D., Laura Leccesi, M.D., Giuseppe Nanni, M.D., Alfons Pomp, M.D., Marco Castagneto, M.D., Giovanni Ghirlanda, M.D., and Francesco Rubino, M.D., March 26, 2012.
In this single-center, nonblinded, randomized, controlled trial, 60 patients between the ages of 30 and 60 years with a body-mass index (BMI, the weight in kilograms divided by the square of the height in meters) of 35 or more, a history of at least 5 years of diabetes, and a glycated hemoglobin level of 7.0% or more were randomly assigned to receive conventional medical therapy or undergo either gastric bypass or biliopancreatic diversion. The primary end point was the rate of diabetes remission at 2 years (defined as a fasting glucose level of <100 mg per deciliter [5.6 mmol per liter] and a glycated hemoglobin level of <6.5% in the absence of pharmacologic therapy). Read More
Posted by Staff
Clinical Trials
Wednesday, March 28th, 2012
New England Journal of Medicine: Philip R. Schauer, M.D., Sangeeta R. Kashyap, M.D., Kathy Wolski, M.P.H., Stacy A. Brethauer, M.D., John P. Kirwan, Ph.D., Claire E. Pothier, M.P.H., Susan Thomas, R.N., Beth Abood, R.N., Steven E. Nissen, M.D., and Deepak L. Bhatt, M.D., M.P.H., March 26, 2012.
In this randomized, nonblinded, single-center trial, we evaluated the efficacy of intensive medical therapy alone versus medical therapy plus Roux-en-Y gastric bypass or sleeve gastrectomy in 150 obese patients with uncontrolled type 2 diabetes. The mean (±SD) age of the patients was 49±8 years, and 66% were women. The average glycated hemoglobin level was 9.2±1.5%. The primary end point was the proportion of patients with a glycated hemoglobin level of 6.0% or less 12 months after treatment. Read More
Posted by Staff
Clinical Trials
Wednesday, March 28th, 2012
Care.diabetesjournals.org: March 26, 2012.
OBJECTIVE Metformin produced weight loss and delayed or prevented diabetes in the Diabetes Prevention Program (DPP). We examined its long-term safety and tolerability along with weight loss, and change in waist circumference during the DPP and its long-term follow-up.
RESEARCH DESIGN AND METHODS The randomized double-blind clinical trial of metformin or placebo followed by a 7–8-year open-label extension and analysis of adverse events, tolerability, and the effect of adherence on change in weight and waist circumference. Read More
Posted by Staff
Clinical Trials
Wednesday, March 28th, 2012
ScienceDaily (Mar. 22, 2012) — A common high-blood-pressure medication appears to reverse the diabetes-related death of pancreatic beta cells, according to a University of Alabama at Birmingham study published March 22 in the journal Diabetes.
The authors argue that the findings — while in human pancreatic islets and diabetic mice — could have clinical implications as physicians consider that calcium channel blockers may address two major, related diseases. They also found evidence in past clinical trials that the study drug verapamil may slow diabetes.
Beta cells secrete insulin to control blood sugar levels, but begin to die as patients develop Type 1 or Type 2 diabetes. No one suspected that calcium channel blockers might reverse beta cell death because the studies that led to their FDA approval measured their effect on heart attacks, not blood sugar. UAB researchers were surprised when hints of verapamil’s effect were discovered amid their effort to design a drug to shut down a protein called TXNIP. Read more
